Tempest Therapeutics (NASDAQ:TPST) Shares Up 1.1% – Here’s Why

Tempest Therapeutics, Inc. (NASDAQ:TPST)’s stock price shot up 1.1% during trading on Wednesday . The stock traded as high as $2.97 and last traded at $2.87. 100,280 shares traded hands during trading, an increase of 7% from the average session volume of 94,017 shares. The stock had previously closed at $2.84.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Tempest Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, October 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tempest Therapeutics in a research report on Monday. Two investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Reduce” and a consensus target price of $12.50.

Tempest Therapeutics Trading Up 1.1%

The stock has a market cap of $14.15 million, a P/E ratio of -0.29 and a beta of -2.43. The company’s fifty day simple moving average is $5.73 and its 200-day simple moving average is $7.75.

Tempest Therapeutics (NASDAQ:TPST) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.79) EPS for the quarter, topping analysts’ consensus estimates of ($3.27) by $2.48. As a group, analysts expect that Tempest Therapeutics, Inc. will post -1.39 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tempest Therapeutics

An institutional investor recently raised its position in Tempest Therapeutics stock. Vanguard Group Inc. lifted its stake in Tempest Therapeutics, Inc. (NASDAQ:TPST) by 20.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 162,560 shares of the company’s stock after buying an additional 27,952 shares during the period. Vanguard Group Inc. owned about 3.66% of Tempest Therapeutics worth $1,671,000 at the end of the most recent reporting period. Institutional investors own 22.52% of the company’s stock.

Tempest Therapeutics Company Profile

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.